lf you are attending #AACR2024, we invite you to come to our oral presentation, where we'll discuss development of Claudin18.2 IHC 14G11 pharmDx as a clinical trial assay for the clinical development of anti-Claudin 18.2 monoclonal antibody Osemitamab (TST001) in gastric and gastroesophageal junction adenocarcinoma.
Novel Technologies for Precision Medicine: Agilent Avida Targeted Sequencing and Claudin 18.2 IHC Assay for Transcenta Therapeutics’ Osemitamab Program Visit Spotlight Theater D - April 7, 2024 at 3:30 PM Register here: https://bit.ly/3TvPFhg